Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021
Authors
Keywords
-
Journal
Cancer Medicine
Volume 5, Issue 7, Pages 1416-1424
Publisher
Wiley
Online
2016-04-25
DOI
10.1002/cam4.713
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy
- (2014) A. Gajjar et al. CLINICAL CANCER RESEARCH
- Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas
- (2014) Andrew D. Norden et al. JOURNAL OF NEURO-ONCOLOGY
- Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound
- (2013) Ahmed El Kaffas et al. ANGIOGENESIS
- Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children's Oncology Group
- (2013) T. J. MacDonald et al. NEURO-ONCOLOGY
- A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma
- (2012) Edward Pan et al. JOURNAL OF NEURO-ONCOLOGY
- A phase I/II trial of vandetanib for patients with recurrent malignant glioma
- (2012) T. N. Kreisl et al. NEURO-ONCOLOGY
- The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma
- (2012) Randy D’Amico et al. NEUROLOGICAL RESEARCH
- A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies
- (2011) Evan J. Wuthrick et al. CANCER
- Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study
- (2011) Steven G. DuBois et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study
- (2011) S. G. DuBois et al. CLINICAL CANCER RESEARCH
- Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease
- (2010) Barbara S. Paugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of sunitinib malate in patients with recurrent high-grade glioma
- (2010) B. Neyns et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
- (2010) F. M. Iwamoto et al. NEURO-ONCOLOGY
- Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors
- (2009) Marjut Puputti et al. BRAIN PATHOLOGY
- Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma
- (2009) S. Stacchiotti et al. CLINICAL CANCER RESEARCH
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
- (2009) B. E. Houk et al. CLINICAL CANCER RESEARCH
- Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
- (2009) G. D. Demetri et al. CLINICAL CANCER RESEARCH
- Efficacy of Sunitinib and Radiotherapy in Genetically Engineered Mouse Model of Soft-Tissue Sarcoma
- (2009) Sam S. Yoon et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started